FindTrial
Sign In

Fib to Alb Ratio in Type 2 Dkd

Fibrinogen to Albumin Ratio (FAR) as a Risk Factor for Type 2 Diabetic Nephropathy(DN)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05691985
Enrollment
50
Registered
2023-01-20
Start date
2024-07-25
Completion date
2025-10-15
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD, Type 2 Diabetes

Brief summary

Aimed to investigate the association of fibrinogen to albumin ratio (FAR) with DKD type 2 and to prove its possible role as a novel biomarker to predict and prevent DKD progression.

Detailed description

Diabetic kidney disease (DKD) is the most prevalent chronic kidney disease. Around 3540% of patients with type 2 diabetes mellitus (T2DM) will go on to develop DKD. DKD is characterized by albuminuria and reduced estimated glomerular filtration rate (eGFR), both of which are independent risk factors for end-stage kidney disease (ESKD), cardiovascular events, and death. DKD accounts for a significant increase in mortality among diabetic patients and is a grave threat to their clinical outcome. Inflammation plays a major role in the development of DKD. Serum fibrinogen (FIB) is a biomarker of coagulation and inflammation. Elevated serum FIB is an independent risk factor of DKD progression to ESKD in patients with T2DM. Albumin (ALB) has anti-inflammatory functions and antioxidant properties. Hypoalbuminemia is associated with a poorer renal prognosis in patients with T2DM and DKD. Fibrinogen to albumin ratio (FAR) is a more significant prognostic marker than each single marker itself in cancer study.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* Age above 18 yrs. * 50 Pts with type 2 DM that have DKD (presence of albuminuria in association with diabetic retinopathy) and 50 pts with type 2 DM but have no DKD.

Exclusion criteria

* Age below 18 yrs. * Pts with ESKD, manifested cardiac valvular disease, acute infection, history of hepatitis, pts with DKA and Cancer. * Pt who refused to contribute in this study

Design outcomes

Primary

MeasureTime frameDescription
The association of fibrinogen to albumin ratio (FAR) with DKD type 2.baselineinvestigate the association of fibrinogen to albumin ratio (FAR) with DKD type 2.

Countries

Egypt

Contacts

STUDY_DIRECTOREssam Abdelmonem Sadek, Prof

Assiut University

STUDY_DIRECTORMohamed Hassan Mustafa, Dr

Assiut University

PRINCIPAL_INVESTIGATORAbdallah Gamal Abd El Hafeez, Resident

Assiut University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 10, 2026